A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Trial Title: A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

NCT ID: NCT06207305

Condition: Metastatic Appendiceal Adenocarcinoma
Intraperitoneal Paclitaxel

Conditions: Official terms:
Adenocarcinoma
Diphenhydramine
Promethazine
Dexamethasone
Paclitaxel
Famotidine

Study type: Interventional

Study phase: Phase 1/Phase 2

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Dexamethasone
Description: Given by PO
Arm group label: Phase I/Phase II

Other name: Decadron

Intervention type: Drug
Intervention name: Diphenhydramine
Description: Given by PO
Arm group label: Phase I/Phase II

Other name: Benadryl®

Intervention type: Drug
Intervention name: Famotidine
Description: Given by PO
Arm group label: Phase I/Phase II

Other name: Pepcid®

Intervention type: Drug
Intervention name: Paclitaxel
Description: Given by PO
Arm group label: Phase I/Phase II

Other name: Taxol

Summary: To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.

Detailed description: Primary (Phase I): 1. To assess the maximum tolerated dose (MTD) of paclitaxel via IP route given every 14 days in subjects with metastatic appendiceal adenocarcinoma Primary (Phase II): 2. To assess the pathologic and radiographic objective response rate of paclitaxel via IP route in participants with metastatic appendiceal adenocarcinoma Secondary Objectives 1. To assess the progression-free and overall survival of metastatic appendiceal adenocarcinoma treated with IP paclitaxel. Although the clinical benefit of this drug has not yet been established, the intent of offering this treatment is to provide a possible therapeutic benefit, and thus the participants will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability 2. To assess the pharmacokinetics of IP PTX 3. To assess the change in PCI following IP PTX in patients with metastatic appendiceal adenocarcinoma 4. To assess rate of initially unresectable participants with metastatic appendiceal adenocarcinoma able to undergo CRS / HIPEC after IP PTX 5. To assess the rate of conversion from positive to negative cytology in peritoneal fluid following IP PTX in participants with metastatic appendiceal adenocarcinoma 6. To assess the prognostic value of circulating tumor DNA (ctDNA) in participants with metastatic appendiceal adenocarcinoma and the correlation of quantitative ctDNA measurement with radiographic and pathologic response 7. To generate PDX and PDO models of appendiceal adenocarcinoma and evaluate their ability to predict response of human tumors 8. To evaluate the effect of IP PTX on the transcriptomic state of appendiceal adenocarcinoma and the tumor microenvironment (TME) through comparison of pre- and post-treatment specimens 9. To assess the impact of GNAS, KRAS, TP53, and APC mutation on response to IP PTX therapy 10. To assess the impact of mucinous, signet ring cell, and goblet cell histology on response to IP PTX therapy

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Age 18 years and above. There will be no upper age restriction 2. ECOG performance status ≤ 2 3. Participants must have histologically confirmed diagnosis of unresectable locally metastatic appendiceal adenocarcinoma 4. Metastatic disease in the peritoneal cavity and not a candidate for cytoreductive surgery 5. Participants must have adequate organ and marrow function as defined below: leukocytes ≥3000/mcL absolute neutrophil count ≥1,500/mcL platelets ≥75,000/mcL total bilirubin ≤ institutional upper limit of normal (ULN) creatinine ≤ 1.5X institutional ULN 6. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated 7. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load 8. Participants with metastases outside the peritoneal cavity are not eligible for enrollment 9. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial 10. The effects of PTX on the developing human fetus are unknown. For this reason, and because Taxane agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: 1. Postmenopausal (no menses in greater than or equal to 12 consecutive months) 2. History of hysterectomy or bilateral salpingo-oophorectomy 3. Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy) 4. History of bilateral tubal ligation or another surgical sterilization procedure Approved methods of birth control are as follows: Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of paclitaxel administration. 11. Ability to understand and the willingness to sign a written informed consent document 14) English and non-English-speaking participants Exclusion Criteria: 1. Active infection such as pneumonia or wound infections that would preclude protocol therapy 2. Participants with unstable angina or New York Heart Association (NYHA) Grade II or greater congestive heart failure 3. Participants deemed unable to comply with study and/or follow-up procedures (i.e., cognitive impairment) 4. Participants with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity 5. Previous surgery that would preclude safe diagnostic laparoscopy with port placement 6. Participants who have not recovered from adverse events (AE) due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia 7. Participants who are receiving any other investigational agents 8. Participants with metastases outside the peritoneal cavity 9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to PTX or other agents used in study 10. Participants with psychiatric illness/social situations that would limit compliance with study requirements Participants who are pregnant

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: MD Anderson Cancer Center

Address:
City: Houston
Zip: 77303
Country: United States

Status: Recruiting

Contact:
Last name: Beth Helmink, MD

Phone: 832-696-5784
Email: bhelmink@mdanderson.org

Investigator:
Last name: Beth Helmink, MD
Email: Principal Investigator

Start date: January 30, 2024

Completion date: January 2, 2028

Lead sponsor:
Agency: M.D. Anderson Cancer Center
Agency class: Other

Source: M.D. Anderson Cancer Center

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06207305
http://www.mdanderson.org